AR020323A1 - Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos - Google Patents

Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos

Info

Publication number
AR020323A1
AR020323A1 ARP990102313A ARP990102313A AR020323A1 AR 020323 A1 AR020323 A1 AR 020323A1 AR P990102313 A ARP990102313 A AR P990102313A AR P990102313 A ARP990102313 A AR P990102313A AR 020323 A1 AR020323 A1 AR 020323A1
Authority
AR
Argentina
Prior art keywords
group
amino
substituted
alkyl
mono
Prior art date
Application number
ARP990102313A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020323(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR020323A1 publication Critical patent/AR020323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

Preparaciones farmacéuticas que incluyen derivados del ácido 4-amino-3-sustituido-butanoico, que son efectivos para bloquear los grupos aminoy carboxilo, y un aminoácido alfa para obtener una estabilidad superior en almacenamiento, no solo en laform a de solucion sino también en estadosolido. Dichos derivados comprenden preferentemente gabapentina, pregabalina, bacolofeno y otros. Una preparacion farmacéutica estabilizada, con underivado del ácido 4-amino-3-sustituido-butanoico de formula(1), d onde R1 es un átomo de hidrogeno, un grupo hidroxilo, un grupo metilo o un grupo etilo;R2 es un grupo monovalente seleccionado a partir de: un grupo alquilo recto o ramificado C3-8; un grupo alquileno recto o ramificado C3-8; ungrupo alquilorecto o ramificado C3-8 que es mono- o di-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupo hidroxilo, un grupoalcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, un grupo oxo, un grupo carboxilo o un grupo carboalcoxi;un grupo cicloalquilo C3-8; ungrupo cicloalquilo C3-8 que es mono-, di- o tri-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupo hidroxilo, un grupo alquilo, un grupoalcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, ungrupo ox o, un grupo carboxil o un grupo carboalcoxi; un grupo de anillo condensado formadopor orto-fusion de un anillo fenilo con un grupo cicloalquilo C4-8; un grupo de anillo condensado formado por orto-fusion de un anillo fenilocon un grupocicloalquilo C 4-8 donde dicho anillo fenilo es mono-, di- o tri-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupohidroxilo, un grupo alquilo, un grupo alcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, un grupocarboxilo o un grupo c arboalcoxi; un grupo de anillocondensado formado por orto-fusion de un anillo fenilo con un grupo cicloalquenilo C5-8 o un grupo cicloalcanodienilo C5-8 donde dicho anillo es mono-,di-, o tri-sustituido con un átomo dehalogeno, un grupo trifluoromet ilo, un grupo hidroxilo, un grupo alquilo, un grupo alcoxi, un grupo alquiltio,
ARP990102313A 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos AR020323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15

Publications (1)

Publication Number Publication Date
AR020323A1 true AR020323A1 (es) 2002-05-08

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102313A AR020323A1 (es) 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos

Country Status (37)

Country Link
US (1) US7309719B1 (es)
EP (1) EP1077692B1 (es)
JP (1) JP4612923B2 (es)
KR (1) KR100602047B1 (es)
CN (1) CN1303991C (es)
AR (1) AR020323A1 (es)
AT (1) ATE271864T1 (es)
AU (1) AU768277B2 (es)
BR (1) BR9910508B1 (es)
CA (1) CA2327285C (es)
CO (1) CO5021224A1 (es)
CR (1) CR6026A (es)
CU (1) CU23253B7 (es)
DE (1) DE69918977T2 (es)
DK (1) DK1077692T3 (es)
EG (1) EG26803A (es)
ES (1) ES2221385T3 (es)
GT (1) GT199900069A (es)
HK (1) HK1036586A1 (es)
HN (1) HN1999000072A (es)
HU (1) HU228771B1 (es)
ID (1) ID27724A (es)
IL (2) IL139298A0 (es)
IS (1) IS2233B (es)
MY (1) MY157878A (es)
NO (1) NO328959B1 (es)
NZ (1) NZ508015A (es)
PA (1) PA8472801A1 (es)
PE (1) PE20000556A1 (es)
PL (1) PL204921B1 (es)
PT (1) PT1077692E (es)
SI (1) SI1077692T1 (es)
SV (1) SV1999000064A (es)
TW (1) TWI243054B (es)
UY (1) UY25512A1 (es)
WO (1) WO1999059573A1 (es)
ZA (1) ZA200006484B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
CN1447684A (zh) * 2000-06-16 2003-10-08 特瓦制药工业有限公司 具有在可控制范围内的pH值的稳定的加巴喷丁
PT1289364E (pt) * 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
PT1395242E (pt) 2001-05-25 2006-11-30 Warner Lambert Co Composição farmacêutica líquida
JP2007520547A (ja) * 2004-02-04 2007-07-26 アレムビック・リミテッド ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
WO2005115372A1 (en) * 2004-05-17 2005-12-08 Odessa Pharma, Llc Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
ES2840748T3 (es) 2009-05-19 2021-07-07 Neuroderm Ltd Composiciones para la administración continua de inhibidores de dopa decarboxilasa
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
MX348225B (es) 2010-11-15 2017-05-31 Neuroderm Ltd Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
CN107693486A (zh) 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
WO2015114509A1 (en) 2014-01-28 2015-08-06 Ranbaxy Laboratories Limited Stabilized gastroretentive tablets of pregabalin
PT3116475T (pt) 2014-03-13 2020-12-15 Neuroderm Ltd Composições de inibidores de dopa-descarboxilase
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
EP2929878A1 (en) * 2014-04-09 2015-10-14 Arven Ilac Sanayi ve Ticaret A.S. Extended release formulations of gabapentin
EP3302425A4 (en) 2015-05-26 2018-12-26 Isa Odidi Controlled extended release pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
CN113164423A (zh) 2018-10-04 2021-07-23 美德阿利克斯株式会社 用非水溶剂稳定化的制剂
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
CN114599397B (zh) 2019-10-25 2024-05-28 国立大学法人京都大学 Tau蛋白病的预防或治疗剂
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
SK283281B6 (sk) * 1992-05-20 2003-05-02 Northwestern University Deriváty gamaaminomaslovej kyseliny, spôsoby a medziprodukty na ich výrobu, ich použitie a farmaceutické prostriedky
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
CA2261570A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
IL126999A (en) * 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
ES2380287T3 (es) * 2001-06-11 2012-05-10 Xenoport, Inc. Profármacos de análogos de GABA, composiciones y sus usos

Also Published As

Publication number Publication date
WO1999059573A9 (en) 2000-05-04
PT1077692E (pt) 2004-12-31
PL204921B1 (pl) 2010-02-26
IS2233B (is) 2007-04-15
ES2221385T3 (es) 2004-12-16
IL139298A (en) 2009-07-20
AU4073599A (en) 1999-12-06
HN1999000072A (es) 2000-06-05
IL139298A0 (en) 2001-11-25
DE69918977D1 (de) 2004-09-02
PL344218A1 (en) 2001-10-08
JP2000034226A (ja) 2000-02-02
KR100602047B1 (ko) 2006-07-19
EP1077692B1 (en) 2004-07-28
HU228771B1 (en) 2013-05-28
CA2327285C (en) 2005-06-14
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
GT199900069A (es) 2000-11-04
CO5021224A1 (es) 2001-03-27
ID27724A (id) 2001-04-26
DE69918977T2 (de) 2005-07-28
CR6026A (es) 2008-08-26
DK1077692T3 (da) 2004-12-06
HK1036586A1 (en) 2002-01-11
NO328959B1 (no) 2010-06-28
IS5666A (is) 2000-10-16
WO1999059573A1 (en) 1999-11-25
KR20010043611A (ko) 2001-05-25
SV1999000064A (es) 2000-03-31
TWI243054B (en) 2005-11-11
BR9910508B1 (pt) 2012-01-24
CU23253B7 (es) 2007-12-17
JP4612923B2 (ja) 2011-01-12
CA2327285A1 (en) 1999-11-25
NO20005768D0 (no) 2000-11-14
US7309719B1 (en) 2007-12-18
HUP0102022A3 (en) 2002-11-28
SI1077692T1 (en) 2004-10-31
CN1303991C (zh) 2007-03-14
PE20000556A1 (es) 2000-08-10
BR9910508A (pt) 2001-01-02
EG26803A (en) 2014-09-21
NO20005768L (no) 2000-11-14
UY25512A1 (es) 1999-07-19
CN1301155A (zh) 2001-06-27
ZA200006484B (en) 2002-02-11
MY157878A (en) 2016-07-29
AU768277B2 (en) 2003-12-04
ATE271864T1 (de) 2004-08-15
HUP0102022A2 (hu) 2001-11-28
EP1077692A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
AR020323A1 (es) Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos
MX2009004424A (es) Peptidos inhibidores de la exocitosis neuronal.
ATE510852T1 (de) Dermopharmazeutisch und kosmetisch wirksame oligopeptide
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
DE122009000040I1 (de) Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
ES2083123T3 (es) Nuevos derivados de aril-etil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
FI80877B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening.
MX9102241A (es) Analogos de gaba y de acido l-glutamico para tratamiento contra ataques.
ATE17242T1 (de) Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
AR033356A1 (es) Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
KR940008681A (ko) 디클로페낙 염용 비경구 용액
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
KR910006241A (ko) 피리미딘-4,6-디카복실산 디아미드, 이의 제조방법, 이의 용도 및 이들 화합물을 기초로 하는 약제
PE20000542A1 (es) Composiciones que contienen gabapentina o pregabalina y un humectante
DE68920965D1 (de) Zentralnervensystem wirksame Chromanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
RU2019118696A (ru) Фармацевтические композиции, содержащие инсулин
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
AR035451A1 (es) Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion.
McLamore et al. THE STRUCTURE AND SYNTHESIS OF A NEW THIAZOLIDONE ANTIBIOTIC1
ES8608502A1 (es) Procedimiento para la obtencion de benzofuranonas
ES2107688T3 (es) Compuestos triciclicos con actividad farmaceutica.
ES543804A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dialquilaminoalcoxi sustituido y de sus sa-les de adicion acidas y amonicas cuaternarias
KR950700233A (ko) 아미노산 유도체 및 항활성산소제(Amino acid derivatives and anti-active oxygen agents)
Peters et al. Preparation and pharmacological properties of 4-hydroxymethyl-2-(3′-amino-4′-hydroxyphenyl)-1: 3-dithia-2-arsacyclopentane (Mapharside-BAL compound)
BR9907166A (pt) Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina

Legal Events

Date Code Title Description
FG Grant, registration